Ototoxic drugs are medications that can damage the inner ear, leading to hearing loss, tinnitus (ringing in the ears), or balance problems. More than 200 medications are known to carry some degree of ototoxic risk, but a handful of drug classes cause the vast majority of cases. The damage ranges from mild, fully reversible ringing in the ears to permanent, profound hearing loss, depending on the drug, the dose, and individual risk factors.
How These Drugs Damage the Inner Ear
Your inner ear contains thousands of tiny sensory hair cells that convert sound vibrations into electrical signals your brain can interpret. These cells also help you maintain balance. Ototoxic drugs damage or destroy these hair cells, and in humans, they do not regenerate. The common thread across nearly all ototoxic medications is that they trigger a flood of harmful molecules called reactive oxygen species inside these cells. This oxidative stress overwhelms the cell’s defenses and triggers cell death.
Some drugs also disrupt the chemical environment of the inner ear itself. The inner ear maintains a unique fluid called endolymph with a precise balance of potassium and sodium ions, generated by a structure called the stria vascularis on the inner ear’s wall. This fluid carries a positive electrical charge (about +80 millivolts) that is essential for hearing sensitivity. Certain medications, particularly diuretics, interfere with the ion pumps in this structure, causing that electrical charge to drop and hearing to temporarily fade.
Aminoglycoside Antibiotics
Aminoglycosides are among the most consistently damaging ototoxic drugs. These are powerful antibiotics used for serious bacterial infections, and hearing loss from aminoglycosides is permanent. Studies report ototoxicity rates ranging widely, from near zero to 63%, depending on the dose and how carefully hearing is monitored. In children, hearing loss has been documented in up to 57% of those treated.
Not all aminoglycosides affect the ear in the same way. Some primarily damage the hearing organ (the cochlea), while others target the balance system (the vestibular organs). Neomycin is considered the most toxic to the ear overall. Gentamicin and streptomycin tend to damage balance more than hearing, which is why gentamicin is sometimes deliberately used in tiny doses to treat severe vertigo disorders. Amikacin, neomycin, and kanamycin primarily affect hearing. Tobramycin damages both systems roughly equally.
Platinum-Based Chemotherapy
Cisplatin is one of the most widely used and most ototoxic chemotherapy agents. A large meta-analysis found that about 49% of patients treated with cisplatin alone develop measurable hearing loss. When cisplatin and carboplatin are used together, rates climb to roughly 56%. Carboplatin on its own is significantly less damaging, with hearing loss occurring in about 13% of patients.
The hearing loss from platinum-based chemotherapy typically starts in the high frequencies, meaning you might first notice difficulty understanding speech in noisy environments or lose the ability to hear high-pitched sounds like bird calls or children’s voices. The damage is caused by the same oxidative stress pathway as aminoglycosides, and it is usually permanent. Children are particularly vulnerable, and the effects can worsen even after treatment ends.
Loop Diuretics
Loop diuretics, commonly prescribed for heart failure and severe fluid retention, work by blocking ion transporters in the kidneys. Unfortunately, very similar ion transporters exist in the stria vascularis of the inner ear. When these drugs reach the inner ear, they disrupt potassium recycling and cause the electrical charge in the cochlear fluid to drop, reducing hearing sensitivity.
The good news is that this type of hearing loss is usually temporary and resolves once the drug is stopped or the dose is reduced. However, the risk increases sharply when the drug is given intravenously at high speed. The FDA notes that ototoxicity from furosemide (the most common loop diuretic) is associated with rapid injection, doses above the recommended range, and poor kidney function. For intravenous use, infusion rates are kept at or below 4 milligrams per minute to minimize ear damage. The risk also jumps significantly when loop diuretics are given alongside aminoglycosides, because the diuretic temporarily opens the door for more of the antibiotic to enter the inner ear.
Aspirin and NSAIDs
High-dose aspirin is a classic cause of reversible ototoxicity. At doses of 6 to 8 grams per day (far above the standard one or two tablets), aspirin reliably causes tinnitus and mild hearing loss. In one documented case, a person who ingested 10 grams of aspirin developed severe hearing loss and intense tinnitus within 22 hours, but after the drug cleared, hearing tests confirmed full recovery of the outer hair cells responsible for the damage.
With short-term use, aspirin-related hearing changes appear to be completely reversible. Long-term high-dose use, however, may cause a distinct form of nerve damage in the inner ear that doesn’t fully reverse. It’s also worth noting that chronic low-dose aspirin (the kind people take daily for heart health) can cause tinnitus on its own, even without measurable hearing loss.
Antimalarial Medications
Chloroquine and hydroxychloroquine, used for malaria prevention and autoimmune conditions like lupus and rheumatoid arthritis, can cause sensorineural hearing loss. A systematic review confirmed that both drugs are capable of damaging the cochlea, including the stria vascularis and sensory hair cells. The hearing loss reported in studies was sensorineural (originating in the inner ear rather than the middle ear), with varying degrees of severity and no consistent pattern on hearing tests. The overall evidence base is still limited, with most studies classified as low-quality, but the ototoxic potential is real and worth monitoring in long-term users.
Symptoms and When They Appear
Tinnitus is usually the first warning sign. You might notice ringing, buzzing, or hissing in one or both ears. This often signals that hearing loss is beginning, even if you can’t yet tell that your hearing has changed. Other early symptoms include a sense of fullness in the ears, difficulty following conversations (especially with background noise), and trouble with balance or a new sensation of dizziness or vertigo.
The timeline varies enormously. Some people notice symptoms as soon as they start a medication. Others develop hearing changes gradually over weeks or months. In some cases, ototoxicity doesn’t become apparent until up to five years after starting treatment. Platinum-based chemotherapy is particularly known for this delayed effect, which is why long-term monitoring matters.
Risk Factors That Increase Damage
Several factors amplify ototoxic risk beyond the drug itself. Poor kidney function is one of the most significant, because the kidneys are responsible for clearing most ototoxic drugs from the body. When kidney function is impaired, drug levels stay elevated in the blood longer, giving them more time to accumulate in the inner ear.
Combining two ototoxic drugs is especially dangerous. The classic high-risk combination is an aminoglycoside antibiotic given alongside a loop diuretic. The diuretic disrupts the inner ear’s protective barriers, allowing more of the antibiotic to enter and cause permanent damage. Age also plays a role: very young children and older adults are more susceptible. Prior noise exposure, existing hearing loss, and genetic factors (certain gene variants make some people dramatically more sensitive to aminoglycosides) all further increase vulnerability.
How Hearing Is Monitored
For patients on high-risk medications, structured hearing monitoring programs can catch damage early, sometimes before the patient notices any change. The goal is to establish a baseline hearing test before treatment starts, then retest at regular intervals so that any shift can be detected and the treatment plan adjusted if possible.
For platinum-based chemotherapy, the baseline test should happen within 24 hours of the first treatment, with retesting before every cisplatin session or every third carboplatin session. For aminoglycosides, the baseline window extends to 72 hours after the first dose, with follow-up testing weekly or biweekly during treatment. After treatment ends, hearing tests are recommended within one month and then every three months for the first year. Any detected change in hearing is confirmed by repeat testing within 24 hours.
For patients treated with radiation to the head, monitoring continues much longer: every six months for the first five years, then annually through year ten, because radiation-related hearing loss can develop very gradually.